^(89)SrCl_2治疗多发性骨髓瘤骨痛疗效分析  

Efficacy of ^(89)SrCl_2 in treatment of patients with multiple myeloma

作　　者：刘鹏杰[1,2] 邓智勇[1,2] 唐铭[3] 刘超[1,2] 贾莉[1,2] 陈婷[1,2] 

机构地区：[1]昆明医科大学第三附属医院 [2]云南省肿瘤医院核医学科,云南昆明650118 [3]昆明理工大学附属云南省第一人民医院病理科,云南昆明650002

出　　处：《实用肿瘤杂志》2015年第5期441-443,共3页Journal of Practical Oncology

摘　　要：目的分析89Sr Cl2在治疗多发性骨髓瘤(multiple myeloma,MM)引起的骨痛中的疗效。方法回顾性分析33例Ⅲ期MM伴骨痛患者行89Sr Cl2治疗前及治疗后的KPS评分、VAS评分、骨显像、骨髓像及出现的不良反应。89Sr Cl2治疗1次,剂量4 m Ci。结果89Sr Cl2治疗后1月,KPS评分较治疗前总体升高,且差异有统计学意义(P<0.05);VAS评分总体较治疗前降低,且差异有统计学意义(P<0.05)。治疗后3月,骨显像提示,有效率为39.4%,稳定率为42.4%,无效率为15.2%;骨髓像提示,恶性浆细胞比例治疗前、后差异无统计学意义(P>0.05)。未出现不可逆转的骨髓抑制。结论89Sr Cl2可作为缓解多发性骨髓瘤骨痛的安全有效的治疗手段。Objective To evaluate the efficacy of 89 Sr Cl2 in treatment of patients with multiple myeloma（ MM）.Methods Thirty-three patients with phase Ⅲ MM and bone pain were treated with89 Sr Cl2once（ 4 m Ci）. KPS,VAS,radionuclide bone imaging,bone marrow and adverse effects were evaluated before and after treatment. Results KPS scores raised and VAS scores decreased one month after treatment（ both P〈 0. 05）. Three months after treatment,radionuclide bone imaging showed that the response rate of bone metastases was 39. 4%,the stable rate was 42. 4% and the non-response rate was 15. 2%; there was no significant difference in the percentage of malignant plasma cells in bone marrow before and after treatment（ P 〉0. 05）. No irreversible bone marrow depression was found. Conclusion89 Sr Cl2can be used to treat patients with MM as a safe and effective agent.

关 键 词：多发性骨髓瘤/放射疗法 锶放射性同位素/治疗应用 疼痛/病因学 疼痛/治疗 

分 类 号：R733.3[医药卫生—肿瘤] R730.55[医药卫生—临床医学]